Lisa Degen, PA
Medical · Grand Island, NENPI 1639308893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 47.6% of the total.
Across 131 payments — averaging $11.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$704
- Otsuka America Pharmaceutical, Inc.$120
- Novo Nordisk$109
- Lilly USA, LLC$107
- Abbott$72
- Johnson & Johnson$46
- plus $322 from 14 others
What the payments were for
- Food & beverage$1,480100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $704 |
| Otsuka America Pharmaceutical, Inc. | 7 | $120 |
| Novo Nordisk | 6 | $109 |
| Lilly USA, LLC | 7 | $107 |
| Abbott | 3 | $72 |
| Johnson & Johnson | 3 | $46 |
| Exact Sciences | 2 | $41 |
| AstraZeneca | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $34 |
| GSK | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 5 | $22 |
| Dexcom, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Ardelyx, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pfizer | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Genentech USA, Inc. | 1 | $3 |
How this compares
$1,480 in reported general payments places this provider in the 75th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $30,446 |
| OzempicSemaglutide | 26 | $30,201 |
| TrulicityDulaglutide | 22 | $28,168 |
| MyrbetriqMirabegron | 11 | $14,326 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,525 |
| Nurtec OdtRimegepant Sulfate | 16 | $9,909 |
| JardianceEmpagliflozin | 14 | $8,996 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 24 | $7,470 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 28 | $6,089 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,708 |
| Lacosamide | 12 | $3,053 |
| Omeprazole | 106 | $1,486 |
| Levothyroxine Sodium | 138 | $1,297 |
| Atorvastatin Calcium | 119 | $1,112 |
| Bupropion XlBupropion Hcl | 33 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $14 | $40,35543 claims |
| Novo NordiskOzempic | $109 | $30,20126 claims |
| Lilly USA, LLCTrulicity | $107 | $28,16822 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $30 | $26,08471 claims |
| AstraZenecaSymbicort | $38 | $3,70817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 216 medical providers in Nebraska.
Other medical in Grand Island
- Sara FillGrand Island$1K
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Kelly HooverOmaha$16K
- Lyndsey DegenhardtElkhorn$12K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Shannon BusterPapillion$8K
- Jay ArthurLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.